HIV-1 protease remains an important anti-AIDS drug target. Although it has been known that ligand binding induces large conformational changes in the protease, the dynamic aspects of binding have been largely ignored. Several computational models describing protease dynamics have been reported recently. These have reproduced experimental observations, and have also explained how ligands gain access to the binding site through dynamic behavior of the protease. Specifically, the transitions between three different conformations of the protein have been modeled in atomic detail. Two of these forms were determined by crystallography, and the third was implied by NMR experiments. Based on these computational models, it has been suggested that binding of inhibitors in allosteric sites might affect protease flexibility and disrupt its function.
Introduction
It has been >20 years since HIV was first identified as the causative agent of AIDS [1, 2] . There are currently three main avenues for preventing HIV replication. First, blocking the attachment of virus particles to host-cell surfaces using inhibitors of binding to coreceptors, such as CCR5 [3, 4] . Second, blocking the process of reverse transcription [5] , an approach taken by a major class of anti-AIDS drugs including, for example, AZT, delavirdine, nevirapin, etc. Third, blocking the function of the HIV-1 protease (HIV-1 PR), a process that is described in more detail in this review.
The necessity of HIV-1 PR for virus replication was demonstrated through several experiments. Deletion mutagenesis of the gene encoding HIV-1 PR resulted in the production of virus particles that had an immature morphology and were noninfectious [6] . This was confirmed by mutation of the active site aspartic acids [7] and, later, by chemical inhibition with protease inhibitors [8] . These seminal experiments provided conclusive proof that the viral protease is essential for the life-cycle of HIV, and highlighted this enzyme as an important target for the design of specific antiviral agents.
These findings stimulated further interest in HIV-1 PR, leading to solution of high-resolution 3D structures of HIV-1 PR using X-ray crystallography [9] . Current FDA-approved HIV-1 PR drugs function as active-site inhibitors and serve as a prime example of structurebased rational design (examples of some clinically approved inhibitors are ritonavir, nelfinavir and amprenavir) [10] [11] [12] . Although many successful drugs have been developed, their effectiveness has been hampered by the emergence of drug-resistant variants [13] .
A greater understanding of the mechanistic events associated with the binding of HIV-1 PR substrates and inhibitors is crucially important for the design of novel inhibitors of the enzyme. There is evidence that flexibility of many enzymes plays an important part in inhibitor binding and resistance [14, 15] . This review will focus on recent advances and challenges in understanding protease dynamic behavior and its potential for revealing new approaches to HIV-1 PR inhibitor and drug design. A particular focus is the emergence of computational techniques that can provide a detailed insight into the dynamic aspects of HIV-1 PR behavior. To understand how the substrate gains access to the protease-binding site and how resistance caused by protease mutations arises, many computational studies have been carried out on this enzyme. Recent molecular dynamics (MD) simulations of HIV-1 PR suggested that the dynamics of this enzyme is crucial for its function. Therefore, affecting flexibility of the protease by, for example, allosteric inhibitors, could create new opportunities for inhibitor design.
Experimental data on HIV-1 protease structure: large structural rearrangement on binding An extensive set of X-ray crystal structures of HIV-1 PR, in bound and unbound forms, has been solved [9] , revealing a C2 symmetric homodimer with a large substrate-binding pocket covered by two glycine-rich b-hairpins, or flaps [16] [17] [18] . Consistent structural differences are present between the bound and free states of the protein (Figure 1 ). In all of the liganded forms, the flaps are pulled in towards the bottom of the active site (i.e. the 'closed' form), whereas the structures for the unbound enzyme all adopt a 'semi-open' conformation with the flaps shifted away from the dual Asp25-Thr26-Gly27 catalytic triads, but still substantially closed over the active site and in contact with each other. The non-flap residues show only slight variation. A more striking difference between the two forms is that the orientation (i.e. the 'handedness') of the b-hairpin flaps is reversed (Figure 1a,b) . Although large-scale flap opening is presumably required for normal substrate access to the active site (Figure 1c ), no crystallographic structures representing such an open configuration have been reported. Although the four available crystal structures of unbound HIV-1 PR [16] [17] [18] [19] all show the semiopen conformation, it was not entirely clear whether this reflects the preferred flap conformation or crystal-packing effects [10, 20, 21] . However, it is known from NMR experiments [22, 23] that the flap region has a high degree of flexibility. Based on solution NMR data for the free protease, Torchia and colleagues [23] [24] [25] 
Simulations of HIV-1 protease: exploring flap flexibility
Although X-ray crystallography provides invaluable high-resolution protein structures, they primarily reflect an average structure of a single low-energy conformation with little information on dynamics. NMR experiments can provide a more realistic view of the dynamic behavior of proteins in solution and at more biologically relevant temperatures. Although several HIV-1 PR structures with bound inhibitors were fully solved by solution NMR, so far this technique has not provided structural data for the unbound protease in solution, because of difficulties related to protease autocleavage, as well as its high flexibility in solution.
Computational methods such as MD simulations can provide a detailed, atomic-resolution model for time-dependent structural variation. In addition, these simulations can provide estimates of the energetics associated with different HIV-1 PR states, thus providing insight into thermodynamic aspects involved not only in binding but also in conversion between different protease conformations. Unfortunately, until recently, realistic simulations were hampered by limitations in the model description and timescales that could be reached.
Numerous earlier computational studies have aimed at understanding flap opening dynamics. Collins et al. [26] reported flap opening that results from MD simulations in the gas phase, which involved forcing the atomic coordinates for non-flap regions of a closed structure toward the semi-open state. Scott and Schiffer [27] also observed irreversible flap opening, but the extent of flap opening was not quantitatively described. Instead, the authors focused on the flap tip regions, which curled back into the protein structure during the opening event, burying several hydrophobic residues. This flap 'curling' was hypothesized to provide a key conformational trigger necessary for subsequent large-scale flap The fully 'open' form in which the active site becomes accessible to substrate or inhibitors was not observed in crystal structures but was implied from NMR experiments. The structure shown is from molecular dynamics simulations [35] .
www.drugdiscoverytoday.com 133 opening and, therefore, HIV-1 PR function. A more recent study [28] highlighted the challenges in obtaining accurate simulation data by demonstrating that similar irreversible flap opening could arise from insufficient equilibration during system setup; these artifacts were not observed when more-extensive solvent equilibration was performed. More recently, Hamelberg and McCammon [29] used activated dynamics to produce flap opening in HIV-1 PR. In this case, a trans ! cis isomerization of the Gly-Gly peptide bond was hypothesized to trigger the flap opening. Perryman et al. [30, 31] reported dynamics of the unbound wild-type and a V82F/I84V mutant in which the closed form opened somewhat, but the authors did not report whether the flaps in these unbound protease simulations actually adopted the semi-open flap handedness observed in crystal structures. Nevertheless, the high flexibility of the flaps, particularly for the mutant, was demonstrated and used to investigate active-site inhibitors for the drug-resistant mutant [32] . Importantly, none of these previous computational studies of the free protease reported that the flaps were able to adopt the semi-open conformation from either the open structures that were sampled or, in other cases, from the initial closed conformation. Therefore, it is unclear if such opening events are relevant to the true dynamics of the HIV-1 PR or simply represent an inability of the simulation models to reproduce experimental observations. Recently, several reports were published where multiple and, most importantly, reversible opening of the protease flaps was observed. These works serve as a testimony that simulation methods have finally reached a state where they can provide valuable insights into enzyme function on biologically relevant timescales.
McCammon and co-workers [33, 34] developed a coarse grain model of HIV-1 PR in which each residue is modeled using a single bead at the position of the C a carbon. This treatment substantially reduces the complexity of the system, enabling the simulations to model behavior on the microsecond timescale. Numerous opening and closing events were seen; these were realized primarily by large lateral movements of the flaps that exposed the binding cavity. However, with the current coarse grain model, the long timescales can only occur through neglect of atomic detail, which comes at the cost of not being able to describe more-subtle differences, such as those observed between closed and semi-open crystal structures. There is also no straightforward way to determine how flap behavior is influenced by dynamics on the atomic level in terms of specific sidechain interactions, or to gain an understanding of how solvation is coupled to dynamics.
Recently, a multiscale model was applied to HIV-1 PR dynamics, in which full atomic detail was maintained for the protease, and aqueous solvent was modeled using a continuum approach [35] . These simulations showed spontaneous conversion between the bound and unbound crystal forms upon removal of an inhibitor, and reversible opening of the flaps. Although the simulations of closed inhibitor-bound HIV-1 PR were stable with no substantial conformational changes (Figure 2a,f) , the behavior of the system changed dramatically if the ligand was not present. Removal of the ligand from the protease resulted in spontaneous conversion of the closed flap conformation to the semi-open form (Figure 2b ), similar to that observed in ligand-free protease crystal structures. Notably, this conversion in the simulations is accompanied by the change in flap handedness that is in agreement with crystal structures (Figure 1 ). These simulations provide further evidence that the semi-open form is the true conformation of unbound HIV-1 PR in solution and that a rearrangement of the binding pocket occurs upon ligand binding.
Another characteristic feature of the semi-open ensemble generated in these MD simulations was that it exhibited much higher flexibility, particularly in the flap region (Figure 2b,g ), compared with the closed ensemble. Simulations initiated from the freeprotease crystal structures showed the same behavior. When these simulations were extended to longer times, flexibility of the flaps produced transient openings with large-scale rearrangements of the flaps and flap tip distances over 20 Å (Figure 2c,d) . These fully open forms can easily accommodate entry of substrates. Importantly, these fully open conformations were only transiently populated, and reproducibly returned to the semi-open state (Figure 2e ), indicating that the opening events were not artifacts caused by instability of the system or a poor-quality model. Full flap opening in the simulations occurred through a concerted downward rotation around the center located in the vicinity of the dimer interface, and resulted in noticeable mutual rotation of the two monomers accompanied by a large upward motion of the flaps. Opening via lateral movements of the flaps, as reported in the coarse grain model [34] , was also observed.
Although the direct observation of the fully open structure and of conversions between three different flap conformations in atomic detail simulations was encouraging, the question of how relevant this open state was for ligand binding remained unanswered. A subsequent study [36] addressed these questions by performing unrestrained, all-atom MD simulations following manual placement of a cyclic urea inhibitor into the substratebinding site of the open protease (Figure 2h ). In these simulations, the inhibitor reproducibly induced the protease to undergo spontaneous conversion to the closed form (Figure 2j ), as seen in all inhibitor-bound HIV-1 PR crystal structures. In a typical trajectory, the inhibitor formed specific hydrogen bonds with one of the catalytic aspartic acids and one flap (Figure 2i ), accelerating the closing process. Subsequently, the other flap closed and helped to pack bulky groups of the inhibitor into the binding pocket (Figure 2j ). These simulations reproduced not only the greater degree of flap closure but also the striking difference in flap handedness between bound and free protease. The transitions between the three forms are summarized in Figure 3 .
Another report [37] used MD constrained to dihedral angle space to speed up the sampling. The authors observed transitions between semi-open and open conformations, although the semiopen structure, following the opening event, did not show close agreement with the crystallographic form, which might have resulted from simplifications used in internal coordinate space dynamics. The same authors followed this report with another study [38] reporting protease flap closing as induced by substrate binding. Once again, flap closing was observed to follow an asymmetric path.
In summary, the recent MD simulations, coming from different groups and using different simulation methodologies and forcefields, provide compelling evidence that the major features of protease dynamics are reproduced and are independent of specific system setup details. These studies also serve as a clear indication that the flexibility and the dynamic behavior of HIV-1 PR are amenable to computational analysis, and the resulting data can form the foundation of a flexibility-based drug-design process.
Proposed molecular mechanisms of resistance
Classical and ab initio MD simulations [39, 40] reveal that protease flexibility modulates the activation free-energy barrier of the enzymatic cleavage reaction. In drug-resistant mutants, the active-site mutations are often associated with mutations that partially restore the enzymatic function (i.e. 'compensatory mutations') and frequently occur in regions that are distant from the active site. The mutations in these positions can enhance the catalytic rate of the protease mutants by affecting the flexibility of the protein. Although the authors provide a plausible explanation of how compensatory mutations work, they do not suggest how this understanding could be extended to the design of drugs that escape protease mutations.
In their earlier MD simulation study, Scott and Schiffer [27] propose a model for overcoming resistance based on an observation of HIV-1 PR conformation with flaps curled such that they enable substrate access to the active site. In this conformation, the hydrophobic tips of the flaps (G 48 GIGG 52 ) curl in and pack against the hydrophobic inside wall of the active-site groove. These authors suggest that this open conformation is crucial and the inhibitors should be designed to lock the flaps in their open conformation, and they also believe that such inhibitors would be less susceptible to the development of drug-resistant variants. Along this line, a crystal structure of the unbound HIV-1 PR for the multiple drug resistant (MDR) 769 isolate [protein databank (PDB) code 1TW7] in a 'wide-open' conformation was recently reported [41] . Unlike all previous experimental structures, the binding pocket is more exposed because of the open conformation of the flaps. Although the structure differs from the open structure proposed by Scott and Schiffer [27] , the idea of resistance remains roughly the same. The authors of MDR protease structure indicate that drug resistance in this strain arises at least partly from the changes in the flap conformation, and presumably from the inability of current inhibitors to induce flap closing. In a recent report, MD simulations were performed for this MDR isolate, starting from the open crystal structure. Although simulations that included crystal-packing contacts reproduced the crystal structure, simulations in solution reproducibly reverted to the semi-open form that is observed in crystal structures of the wild-type protease [42] . The results suggest that, although the mutations might have slightly shifted the balance between these forms, the dominant structure in solution at room temperature remains the semi-open form.
An appealing explanation of resistance was provided by Freire and colleagues based on microcalorimetric measurements of protease-binding thermodynamics [43, 44] . In solution, the peptide substrate has a higher flexibility than the synthetic inhibitors and therefore suffers a higher conformational entropy loss upon binding. By contrast, because of its higher flexibility, the peptide substrate is more amenable to adapt to backbone rearrangements or subtle conformational changes induced by mutations in the protease. The synthetic inhibitors are less flexible, and their capacity to adapt to changes in the geometry of the binding pocket is more restricted.
Computational and experimental studies showed that, in the case of HIV-1 PR, there are differences in thermodynamic stability among the alternate protease forms that should be included when considering ligand-binding affinity. Because the structure of the transient open form was only suggested in recent MD studies, the description to date has focused on thermodynamic differences between closed and semi-open forms. For example, the free energy change calculated by the reaction path method estimated that the semi-open form is more favorable than the closed form, with stabilization contribution primarily coming from the entropic term [45] . This analysis is consistent with NMR relaxation data and is reasonable given the high glycine content of the flap tips. As shown by calorimetric experiments, a large favorable entropy change is also the major driving force for high binding affinity of current HIV-1 PR inhibitors [46, 47] . However, in this case it is the favorable solvation entropy associated with the burial of a large hydrophobic surface upon inhibitor binding. Detailed thermodynamic analysis [46] of wild-type and the active-site-resistant mutant (V82F/I84V) suggests that the mutation lowers the binding affinity in two ways: first, by directly altering the interaction between inhibitors and the protease (i.e. the binding enthalpy and entropy); and, second, indirectly by altering the relative stability of free (i.e. semi-open) and bound (i.e. closed) forms upon inhibitor binding. Importantly, mutations that stabilize the semiopen flap conformation will lower binding affinity because of the increased energy penalty required for rearranging the flaps upon substrate or inhibitor binding. Therefore, the free-energy change associated with the conformational change of the protein has to be included in every accurate calculation of binding affinity.
These few examples of the proposed mechanism of resistance raise several important points: to preserve the function of the mutant protease (i.e. efficiently cleaving the viral polyprotein) the enzyme can introduce alterations in the active site but the correct dynamics or flexibility must be preserved; and/or the active-site changes must be compensated by the flexibility of the substrate. Because the competitive advantage of the synthetic inhibitors' strong binding probably arises from their rigidity, it has been challenging to design flexible inhibitors that bind with higher affinity than the natural substrate, at the same time retaining the ability to adapt to a binding pocket that varies in shape. An example of such a flexible inhibitor is KNI-764 (also known as JE-2147), which was shown to remain potent against MDR protease strains [48] . It was demonstrated by calorimetric measurements [49, 50] that, in contrast to previous inhibitors, these second-generation inhibitors bind strongly because of a favorable enthalpy change.
Another strategy to evade mutations in the active site is to design inhibitors that primarily form interactions with the backbone rather than sidechains of the active site [51, 52] , such that mutations in the binding site might not affect the inhibitor binding. A conceptually different strategy arises from the consideration of HIV-1 PR flexibility. Rather than accommodating changes in shape or affinity of the binding site, one could try to interfere with the dynamics of the protein. Assuming that enzyme dynamics must remain conserved, the virus could have a harder time evolving mutations that would restore the functional dynamics of HIV-1 PR.
Drug design targeting protein flexibility: new allosteric inhibitors
In light of the discussion in this review, an attractive alternative approach to designing protease inhibitors would target the thermodynamic balance of the closed, semi-open and open ensembles. This could be achieved by designing allosteric inhibitors that do not directly compete with substrate for the same binding site, but indirectly change the flexibility of the protease such that the balance of the three states is shifted.
The possibility of allosteric inhibitors of HIV-1 PR was suggested previously [30, 31] . Based on MD simulations that showed anticorrelated behavior between flap opening and compression of the elbow region [31] , targeting of the protease elbow regions as an allosteric site was suggested (see Figure 1b) . However, no experimental evidence to support this hypothesis is yet available. It is interesting to note, however, that the only experimentally determined structure with an open binding pocket [41] (i.e. the discussed crystal structure of the MDR isolate) has a crystal-packing contact involving insertion of residues, from a symmetry-related neighbor, into the elbow region [42] . This observation provides further evidence that this site might be a promising candidate for allosteric inhibition.
Another potential target for allosteric inhibition is the protease dimer interface (see Figure 1b) . NMR experiments measuring backbone-amide chemical-exchange transverse-relaxation rates [24] indicate that the flexibility in the four-stranded b-sheet dimer interface increases upon inhibitor binding. This illustrates coupling between the binding site and the dimer interface. A coupling between active site flaps and the dimmer interface is also observed in the crystal structure of a free HIV-1 PR in which the N-and Ctermini of the two protease monomers were tethered [53] . Unlike all other crystal structures of the free protease, this monomeric protease exhibits the closed flap conformation. Last but not least, there has been a continuing effort to design inhibitors of protease dimerization [54, 55] . An interesting recent report [56] demonstrated that some of the inhibitors that were initially designed to prevent dimerization did not actually disrupt the dimer interface and yet showed substantial protease inhibition. These authors thus concluded that these compounds acted as allosteric inhibitors binding at the dimer interface and indirectly reducing the binding affinity of the substrate.
Further evidence that these sites can provide useful targets for allosteric inhibitors has been shown by Rezacova et al. [57] ; they developed monoclonal antibodies (mAbs) with potent inhibition of HIV-1 PR function. These mAbs targeted two non-binding-site regions of the enzyme: one corresponds to residues 36-46 (i.e. the flap elbow) and the other to residues 1-6 at the dimer interface. The mechanism of inhibition is not clear but the authors suggest that disruption of the native fold, or even the dimerization interface, is a possibility. Yet another example of potentially exploitable allosteric inhibition was reported for b-lactam compounds [58] .
The authors of that study demonstrated that the inhibitors are noncompetitive and that they only interact with ligand-bound enzyme, and suggested a mechanism of inhibition through interaction of b-lactam compounds with the closed flap region of the enzyme-substrate complex.
Although the existence of HIV-1 PR allosteric sites has not yet been shown experimentally, it has been argued that their presence is likely for all dynamic proteins [59] . The allosteric inhibitors do not compete with natural substrate and, thus, their effect is not decreased by a higher substrate concentration. They also have a potential for better selectivity [59] . Moreover, the hydrophobic character of the HIV-1 PR active site leads to hydrophobic protease inhibitors and therefore results in their undesirable poor water solubility [60, 61] . Thus, the additional advantage of the two allosteric sites discussed previously in this review stems from their polar character, which could avoid difficulties with inhibitor solubility.
Concluding remarks
The pronounced differences in bound and unbound protease crystal structures and NMR studies provide experimental evidence that HIV-1 PR flexibility plays a crucial part in its function. Numerous computational studies reviewed here emphasize the importance of protease dynamics in substrate and inhibitor binding. Altogether, this provides new opportunities for developing protease inhibitors in which protease dynamics and flexibility, as determined through computer simulation, are explicitly targeted in the inhibitor-design process. Specifically, influencing the thermodynamics of the three protease states (i.e. closed, semi-open and open) might disrupt HIV-1 PR function. It remains to be seen whether this approach makes it harder for the enzyme to evolve resistant mutations.
Computer simulations aimed at accurate quantitative description of protease dynamics still face challenges, although atomic level and coarse grain simulations complement each other in their predictive abilities. All-atom simulations provide a model that can experimentally reproduce observed structural changes, predict a new open structure inferred from experiments and show transitions between all three forms. By contrast, coarse grain models could provide a more statistically valid thermodynamic description of the flap opening and thereby provide quantitative estimates for the shift in equilibrium arising from protease mutations. To date, the accuracy of the coarse grain model does not seem to be sufficient to reproduce the detailed conformational changes that accompany binding (i.e. changes between closed and semi-open forms). Full atomistic models can therefore serve as an important reference for calibrating and improving the coarse grain models.
In summary, because of improved quality of the computational models and the ability to extend simulations to biologically relevant timescales, computational techniques have finally reached the stage where they can reproduce experimental observations. Perhaps more important, however, is that simulations can now complement experiments by providing valuable insights into dynamic events and energetic aspects of ligand binding and drug resistance. Elsevier.com -linking scientists to new research and thinking
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